Antibodies that target hiv gp120 and methods of use
AssigneeGilead Sciences, Inc.
InventorsMini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
Life of this patent
Estimating the term…
Abstract
Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
Claims35
1-97. (canceled)
An expression vector or expression vectors comprising the nucleic acid molecule or nucleic acid molecules of claim 98 operably linked to a regulatory sequence.
A pharmaceutical composition comprising the nucleic acid molecule or nucleic acid molecules of claim 98, and a pharmaceutically acceptable carrier.
A lipid nanoparticle (LNP) comprising the nucleic acid molecule or nucleic acid molecules of claim 98.
A method of producing an antibody or antigen-binding fragment thereof, the method comprising:
- culturing the host cell of claim 108 in a cell culture;
- and
- isolating the antibody or antigen-binding fragment from the cell culture.
A nucleic acid molecule or nucleic acid molecules encoding an antibody or an antigen-binding fragment thereof that binds to human immunodeficiency virus-1 (HIV-1) Envelope glycoprotein gp120, the antibody or antigen-binding fragment thereof comprising (i) a heavy chain variable region (VH) comprising VH complementary determining regions 1-3 (CDRs 1-3) and (ii) a light chain variable region (VL) comprising VL CDRs 1-3, wherein the VH CDRs 1-3 and VL CDRs 1-3 have the sequences set forth in:
- (i) SEQ ID NOs.:
- 159, 138, 139, 140, 141, and 142, respectively;
- (ii) SEQ ID NOs.:
- 137, 160, 139, 140, 141, and 142, respectively;
- (iii) SEQ ID NOs.:
- 137, 161, 139, 140, 141, and 142, respectively;
- (iv) SEQ ID NOs.:
- 137, 162, 139, 140, 141, and 142, respectively;
- (v) SEQ ID NOs.:
- 137, 163, 139, 140, 141, and 142, respectively;
- (vi) SEQ ID NOs.:
- 137, 138, 164, 140, 141, and 142, respectively;
- (vii) SEQ ID NOs.:
- 159, 138, 164, 140, 141, and 142, respectively;
- (viii) SEQ ID NOs.:
- 137, 138, 139, 140, 165, and 142, respectively;
- (ix) SEQ ID NOs.:
- 137, 138, 139, 140, 166, and 142, respectively;
- (x) SEQ ID NOs.:
- 137, 138, 139, 140, 167, and 142, respectively;
- (xi) SEQ ID NOs.:
- 137, 138, 139, 140, 168, and 142, respectively;
- (xii) SEQ ID NOs.:
- 137, 138, 154, 140, 141, and 142, respectively;
- or
- (xiii) SEQ ID NOs.:
- 137, 138, 139, 140, 141, and 142, respectively;
- and
- wherein the antibody or antigen-binding fragment thereof includes in framework region 3 (FR3) of the VH at position corresponding to 74a, 74b, 74c, and 74d (Kabat numbering) the amino acid sequence set forth in SEQ ID NO:
- 62.
106-107. (canceled)
118-123. (canceled)
126-149. (canceled)
Dependencies are inferred from the claim text.